Skip to main content
PMC home page
Protein & Cell logoLink to Protein & Cell
. 2013 Apr 15;4(5):356–363. doi: 10.1007/s13238-013-2125-y

Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations

Yi Lu 12125,22125, Taijiao Jiang 12125,✉
PMCID: PMC4875545  PMID: 23589018

Abstract

The use of antiviral drugs such as influenza neuraminidase (NA) inhibitors is a critical strategy to prevent and control flu pandemic, but this strategy faces the challenge of emerging drug-resistant strains. For a highly pathogenic avian influenza (HPAI) H5N1 virus, biosafety restrictions have significantly limited the efforts to monitor its drug responses and mechanisms involved. In this study, a rapid and biosafe assay based on NA pseudovirus was developed to study the resistance of HPAI H5N1 virus to NA inhibitor drugs. The H5N1 NA pseudovirus was comprehensively tested using oseltamivir-sensitive strains and their resistant mutants. Results were consistent with those in previous studies, in which live H5N1 viruses were used. Several oseltamivir-resistant mutations reported in human H1N1 were also identified to cause decreased oseltamivir sensitivity in H5N1 NA by using the H5N1 NA pseudovirus. Thus, H5N1 NA pseudoviruses could be used to monitor HPAI H5N1 drug resistance rapidly and safely.

Electronic Supplementary Material

Supplementary material is available for this article at 10.1007/s13238-013-2125-y and is accessible for authorized users.

Keywords: influenza virus, H5N1, neuraminidase inhibitor, drug resistance, pseudovirus

Electronic supplementary material

13238_2013_2125_MOESM1_ESM.pdf (104.4KB, pdf)

Supplementary material, approximately 100 KB.

Footnotes

Electronic Supplementary Material

Supplementary material is available for this article at 10.1007/s13238-013-2125-y and is accessible for authorized users.

References

  1. Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther. 2006;11:971–976. [PubMed] [Google Scholar]
  2. Barrett S, Mohr PG, Schmidt PM, McKimm-Breschkin JL. Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses. PLoS One. 2011;6:e23627. doi: 10.1371/journal.pone.0023627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bavagnoli L, Maga G. The 2009 influenza pandemic: promising lessons for antiviral therapy for future outbreaks. Current Med Chem. 2011;18:5466–5475. doi: 10.2174/092986711798194397. [DOI] [PubMed] [Google Scholar]
  4. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010;328:1272–1275. doi: 10.1126/science.1187816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boivin G, Pizzorno A, Bouhy X, Abed Y. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis. 2011;203:25–31. doi: 10.1093/infdis/jiq010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boltz DA, Douangngeun B, Phommachanh P, Sinthasak S, Mondry R, Obert C, Seiler P, Keating R, Suzuki Y, Hiramatsu H, et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People’s Democratic Republic. J Gen Virol. 2010;91:949–959. doi: 10.1099/vir.0.017459-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Deng YM, Caldwell N, Hurt A, Shaw T, Kelso A, Chidlow G, Williams S, Smith D, Barr I. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses. Antiviral Res. 2011;90:87–91. doi: 10.1016/j.antiviral.2011.02.014. [DOI] [PubMed] [Google Scholar]
  8. Earhart KC, Elsayed NM, Saad MD, Gubareva LV, Nayel A, Deyde VM, Abdelsattar A, Abdelghani AS, Boynton BR, Mansour MM, et al. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Health. 2009;2:74–80. doi: 10.1016/j.jiph.2009.04.004. [DOI] [PubMed] [Google Scholar]
  9. Eshaghi A, Patel SN, Sarabia A, Higgins RR, Savchenko A, Stojios PJ, Li Y, Bastien N, Alexander DC, Low DE, et al. Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerg Infect Dis. 2011;17:1472–1474. doi: 10.3201/eid1708.102004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol. 2008;41:13–19. doi: 10.1016/j.jcv.2007.10.020. [DOI] [PubMed] [Google Scholar]
  11. Garcia JM, Lai JC. Production of influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: an update. Expert Rev Anti Infect Ther. 2011;9:443–455. doi: 10.1586/eri.11.25. [DOI] [PubMed] [Google Scholar]
  12. Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther. 2010;15:1151–1159. doi: 10.3851/IMP1678. [DOI] [PubMed] [Google Scholar]
  13. Hayden FG. Antiviral resistance in influenza viruses—implications for management and pandemic response. N Engl J Med. 2006;354:785–788. doi: 10.1056/NEJMp068030. [DOI] [PubMed] [Google Scholar]
  14. Herfst S, Schrauwen EJA, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, et al. Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets. Science. 2012;336:1534–1541. doi: 10.1126/science.1213362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother. 2009;53:4433–4440. doi: 10.1128/AAC.00334-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, Caldwell N, Freeman K, Komadina N, Smith D, et al. Euro Surveill. 2011. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation; p. 16. [PubMed] [Google Scholar]
  17. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA, Fouchier RAM. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathogens. 2010;6:e1000933. doi: 10.1371/journal.ppat.1000933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature. 2012;486:420–428. doi: 10.1038/nature10831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kuroda H, Kutner RH, Bazan NG, Reiser J. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J Virol Methods. 2009;157:113–121. doi: 10.1016/j.jviromet.2008.11.021. [DOI] [PubMed] [Google Scholar]
  20. Le MT, Wertheim HF, Nguyen HD, Taylor W, Hoang PV, Vuong CD, Nguyen HL, Nguyen HH, Nguyen TQ, Nguyen TV, et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS One. 2008;3:e3339. doi: 10.1371/journal.pone.0003339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005;437:1108. doi: 10.1038/4371108a. [DOI] [PubMed] [Google Scholar]
  22. Legoff J, Rousset D, Abou-Jaoude G, Scemla A, Ribaud P, Mercier-Delarue S, Caro V, Enouf V, Simon F, Molina JM, et al. I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y. PLoS One. 2012;7:e37095. doi: 10.1371/journal.pone.0037095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis. 2007;13:1354–1357. doi: 10.3201/eid1309.070164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Monto AS. The role of antivirals in the control of influenza. Vaccine. 2003;21:1796–1800. doi: 10.1016/S0264-410X(03)00075-6. [DOI] [PubMed] [Google Scholar]
  25. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012;17:159–173. doi: 10.3851/IMP2067. [DOI] [PubMed] [Google Scholar]
  26. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis. 2010;51:983–984. doi: 10.1086/656439. [DOI] [PubMed] [Google Scholar]
  27. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother. 2010;54:3671–3677. doi: 10.1128/AAC.00581-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Peiris JSM, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev. 2007;20:243–267. doi: 10.1128/CMR.00037-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Perez DR. Public health and biosecurity. H5N1 debates: hung up on the wrong questions. Science. 2012;335:799–801. doi: 10.1126/science.1219066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem. 1979;94:287–296. doi: 10.1016/0003-2697(79)90362-2. [DOI] [PubMed] [Google Scholar]
  31. Schmidt PM, Attwood RM, Mohr PG, Barrett SA, McKimm-Breschkin JL. A generic system for the expression and purification of soluble and stable influenza neuraminidase. PLoS One. 2011;6:e16284. doi: 10.1371/journal.pone.0016284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284–3292. doi: 10.1128/AAC.00555-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Su CY, Wang SY, Shie JJ, Jeng KS, Temperton NJ, Fang JM, Wong CH, Cheng YSE. In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. Antiviral Res. 2008;79:199–205. doi: 10.1016/j.antiviral.2008.03.002. [DOI] [PubMed] [Google Scholar]
  34. Tisoncik JR, Guo Y, Cordero K, Yu J, Wang J, Cao Y, Rong L. Identification of critical residues of influenza neuraminidase in viral particle release. Virol J. 2011;8:14. doi: 10.1186/1743-422X-8-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med. 2010;363:1381–1382. doi: 10.1056/NEJMc1003749. [DOI] [PubMed] [Google Scholar]
  36. van der Vries E, Veldhuis Kroeze EJ, Stittelaar KJ, Linster M, Van der Linden A, Schrauwen EJ, Leijten LM, van Amerongen G, Schutten M, Kuiken T, et al. Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog. 2011;7:e1002276. doi: 10.1371/journal.ppat.1002276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol. 2002;12:159–166. doi: 10.1002/rmv.352. [DOI] [PubMed] [Google Scholar]
  38. WHO Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO, http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html.
  39. Xu X, Subbarao, Cox NJ, Guo Y. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology. 1999;261:15–19. doi: 10.1006/viro.1999.9820. [DOI] [PubMed] [Google Scholar]
  40. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, Govorkova EA. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol. 2006;80:8787–8795. doi: 10.1128/JVI.00477-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol. 2007;81:12418–12426. doi: 10.1128/JVI.01067-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Zhang YH, Lin XJ, Wang GQ, Zhou JF, Lu J, Zhao HL, Zhang FW, Wu J, Xu CQ, Du N, et al. Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses. PLoS One. 2010;5:e9167. doi: 10.1371/journal.pone.0009167. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

13238_2013_2125_MOESM1_ESM.pdf (104.4KB, pdf)

Supplementary material, approximately 100 KB.

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES